Kalaris Therapeutics Inc
NASDAQ:KLRS · NASDAQ Global Market
-$0.03 today
Vol 0.05M · Avg 0.08M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-55.1%
avg -18.8%
ROIC
-41.1%
avg 347.5%
ROA
-35.7%
avg -128.6%
Analysis
ROA is currently the strongest return metric at -35.7% versus its period average of -128.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Brett R. Hagen | Chief Accounting Officer and Principal Accounting & Financial Officer | $1.14M | — | 53 | $0.00 | <0.01% |
Andrew Oxtoby | President, Chief Executive Officer & Director | $882,039.00 | — | 52 | $222,000.00 | 1.19% |
Matthew Feinsod | Chief Medical Officer | $665,368.00 | — | 55 | $95,000.00 | 0.51% |
Napoleone Ferrara | Independent Director & Co-Founder | $46,663.00 | — | 69 | $9,000.00 | 0.05% |
Michael Philip Dybbs | Director & Co-Founder | $39,000.00 | — | 51 | $9,000.00 | 0.05% |
Srinivas Akkaraju | Director & Co-Founder | $39,000.00 | — | 58 | $9,000.00 | 0.05% |
Jill E. Porter | Senior Vice President of CMC | — | — | — | — | — |
Kristine Curtiss | Senior Vice President of Clinical | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$6.18M
Sells
1
$12,868.80
Net Sentiment
+$6.17M
Net buying
Most Active
AKKARAJU SRINIVAS
2 transactions
Analysis
Insiders reported 2 buys worth $6.18M and 1 sells worth $12,868.80 over the last 12 months. That adds up to net buying of $6.17M. AKKARAJU SRINIVAS was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
Sutro Biopharma, Inc.
NASDAQ:STRO
$278.70M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$211.08M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$133.48M
Context Therapeutics Inc.
NASDAQ:CNTX
$127.71M
InflaRx N.V.
NASDAQ:IFRX
$115.57M
ImageneBio Inc
NASDAQ:IMA
$63.39M
Metagenomi, Inc. Common Stock
MGX
$45.18M
Quince Therapeutics, Inc.
QNCX
$5.20M
Who manages KLRS?
Kalaris Therapeutics Inc (KLRS) lists 8 active executives. The top listed executive is Matthew Feinsod, Chief Medical Officer.
Are KLRS insiders buying or selling?
Recent insider activity shows net buying of $31.17M.
Explore More
Continue the stock analysis
Jump to another research area for this company.